Cancer Chemotherapy and Pharmacology

, Volume 53, Issue 6, pp 527–532 | Cite as

Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates

  • Patrick A. Thompson
  • Stacey L. Berg
  • Alexander Aleksic
  • Jody Z. Kerr
  • Leticia McGuffey
  • Robert Dauser
  • Jed G. Nuchtern
  • Fred Hausheer
  • Susan M. Blaney
Original Article



BNP1350 (7-[(2-trimethylsilyl)ethyl]-20(S)-camptothecin, karenitecin), a highly lipophilic camptothecin, a high percentage of which is maintained in the active lactone form under physiologic conditions, has recently entered clinical trials in adults and children. BNP1350 has shown significant preclinical antitumor activity against a wide variety of adult and pediatric tumor cell lines. This study was undertaken to define the pharmacokinetics of BNP1350 in both plasma and cerebrospinal fluid (CSF) in a nonhuman primate model.


Four nonhuman primates with indwelling Ommaya reservoirs received BNP1350, 0.1 mg/kg i.v, administered as a 60-min infusion. Frequent plasma and CSF samples were obtained for quantitation of BNP1350 concentrations using reverse-phase high-pressure liquid chromatography (HPLC).


Disappearance of the lactone form from the plasma was biexponential with a mean distribution half-life of 57.5 min (CV ±33%) and an elimination half-life of 457 min (CV ±24%). The volume of distribution for the central compartment was 1.36 l/kg (CV ±27%) and clearance from the central compartment was 10.6 ml/kg per minute (CV ±28%). The peripheral compartment volume of distribution was 1.96 l/kg (CV ±8.4%). Peak CSF lactone concentration, which occurred at 12 to 25 min after the end of the infusion, was 0.33 nM (CV ±71%).


The ratio of the CSF AUC to the plasma AUC was less than 5% (range 0.4% to 3.0%), similar to other highly protein-bound topoisomerase inhibitors such as 9-aminocamptothecin and SN-38 (the active metabolite of irinotecan).


BNP1350 Karenitecin Topoisomerase I inhibitor CSF penetration Pharmacokinetics 


  1. 1.
    Van Hattumm AH, Pinedo HM, Schulper HM, Hausheer FH, Boven E (2000) New highly lipophilic BNP1350 is an effective drug in experimental human cancer. Int J Cancer 88:260–266CrossRefPubMedGoogle Scholar
  2. 2.
    Maxwell Al, Gellert M (1986) Mechanistic aspects of DNA topoisomerases. Adv Protein Chem 38:69–107PubMedGoogle Scholar
  3. 3.
    Johnston RK, McCabe FL, Faucette LF, Hertzberg RP, Kingsbury WD, Boehm JC, Caranfa MJ, Holden KG (1989) SK&F 104864, a water soluble analog of camptothecin with broad-spectrum activity in preclinical tumor models. Proc Am Assoc Res 30:623Google Scholar
  4. 4.
    Liu L (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58:351–375PubMedGoogle Scholar
  5. 5.
    Yao S, Murali D, Seetharamulu P, Haridas K, Petluru PN, Reddy DG, Hausheer FH (1998) Topotecan lactone selectively binds to double- and single-stranded DNA in the absence of topoisomerase I. Cancer Res 58:3782–3786PubMedGoogle Scholar
  6. 6.
    Hausheer FH, Haridas K, Zhao M, Murali D, Seetharamulu P, Yao S, Reddy D, Pavankumar P, Saxe J, Qiuli H, Rustum Y (1997) Karenitecins: a novel class of orally active highly lipophilic topoisomerase I inhibitors. Proc Am Assoc Cancer Res 38:227Google Scholar
  7. 7.
    Hausheer FH, Haridas K, Zhao M, Murali D, Seetharamulu P, Yao S, Reddy D, Pavankumar P, Wu M, Saxe J, Huang Q, Rustum Y (1998) Karenitecins (part II): a novel class of orally active highly lipophilic topoisomerase I inhibitors. Proc Am Assoc Cancer Res 39:420Google Scholar
  8. 8.
    Kerr JZ, Berg SL, Hausheer FH, Blaney SM (1999) Karenitecins: cytotoxicity studies in pediatric tumor cell lines. Proc Am Assoc Cancer Res 40:112Google Scholar
  9. 9.
    Hausheer FH, Cao, S, Kanter P, Haridas K, Zhao M, Murali D, Seetharamulu P, Yao S, Reddy D, Pavankumar P, Saxe J, Huang Q, Chen X, Parker A, Wu M, Martinez N, Rustum Y (1999) Karenitecins: new preclinical developments with BNP1350 a novel highly potent lipophilic camptothecin. Proc Am Assoc Cancer Res 40:111Google Scholar
  10. 10.
    Boven E, Van Hattum A, Schulper H, Erkelens C, Hausheer FH, Pinedo H (1999) BNP1350 is a novel topoisomerase inhibitor with high efficacy when given by oral route. Proc Am Assoc Cancer Res 40:113Google Scholar
  11. 11.
    Keir ST, Hausheer F, Lawless AA, Bigner DD, Friedman HS (2001) Therapeutic activity of 7-[(2-trimethylsilyl)]-20(S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice. Cancer Chemother Pharmacol 48:83–87CrossRefPubMedGoogle Scholar
  12. 12.
    Blaney SM, Cole DE, Godwin K, Sung C, Poplack DG, Balis FM (1993) Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res 53:725–727Google Scholar
  13. 13.
    Blaney SM, Takimoto C, Murry DJ, Kuttesch N, McCully C, Cole DE, Godwin K, Balis FM (1998) Plasma and cerebrospinal pharmacokinetics of 9-aminocamtothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. Cancer Chemother Pharmacol 41:464–468CrossRefPubMedGoogle Scholar
  14. 14.
    Wood JH, Poplack DG, Bleyer WA, Ommaya AK (1977) Primate model for long-term study of intraventricularly or intrathecally administered drugs and intracranial pressure. Science 195:499–501PubMedGoogle Scholar
  15. 15.
    Poplack DG, Bleyer WA, Wood JH, Kostolich M, Savitch JL, Ommaya AK (1977) A primate model for study of methotrexate pharmacokinetics in the central nervous system. Cancer Res 37(7 Pt 1):1982–1985PubMedGoogle Scholar
  16. 16.
    National Institutes of Health (1988) Guide for the care and use of laboratory animals (Department of Health, Education, and Welfare Publication 85-123, revised). US Government Printing Office, Washington DCGoogle Scholar
  17. 17.
    McCully CL, Balis FM, Bacher J, Phillips J, Poplack DG (1990) A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. Lab Anim Sci 40:520–525Google Scholar
  18. 18.
    Smith JA, Hausheer F, Newman RA, Madden TL (2001) Development of a high-performance liquid chromatographic method to determine the concentration of karenitecin, a novel highly lipophilic camptothecin derivative, in human plasma and urine. J Chromatogr B Biomed Sci Appl 759:117–124CrossRefPubMedGoogle Scholar
  19. 19.
    Perrier D, Mayersohn M (1982) Noncompartmental determination of steady state volume of distribution for any mode of administration. J Pharm Sci 71:372–373PubMedGoogle Scholar
  20. 20.
    Knott GD (1979) MLAB: a mathematical modeling tool. Comput Programs Biomed 10:271–280PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Patrick A. Thompson
    • 1
  • Stacey L. Berg
    • 2
  • Alexander Aleksic
    • 2
  • Jody Z. Kerr
    • 2
    • 6
  • Leticia McGuffey
    • 2
  • Robert Dauser
    • 3
  • Jed G. Nuchtern
    • 4
  • Fred Hausheer
    • 5
  • Susan M. Blaney
    • 2
  1. 1.Department of PediatricsBaylor College of MedicineHoustonUSA
  2. 2.Texas Children’s Cancer CenterBaylor College of MedicineHoustonUSA
  3. 3.Department of NeurosurgeryBaylor College of MedicineHoustonUSA
  4. 4.Department of SurgeryBaylor College of MedicineHoustonUSA
  5. 5.BioNumerik Pharmaceuticals, IncSan AntonioUSA
  6. 6.Wyeth ResearchCollegevilleUSA

Personalised recommendations